Mediastinum ganglioneuroblastoma

Summary

Mediastinum ganglioneuroblastoma (MONDO:0001096) is a disease. A subtype of mediastinum neuroblastoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mediastinum ganglioneuroblastoma
Mondo ID	MONDO:0001096
DOID	DOID:10661
NCIT	C6627
UMLS	C1334653
MedGen	235308
GARD	0022880
Anatomy (UBERON)	UBERON:0003728
Is cancer (heuristic)	no

Also known as: ganglioneuroblastoma (disease) of mediastinum · ganglioneuroblastoma of mediastinum · ganglioneuroblastoma of the mediastinum · mediastinal ganglioneuroblastoma · mediastinum ganglioneuroblastoma (disease)

Disease family

This is a subtype of mediastinum neuroblastoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peripheral nervous system neoplasm › mediastinal neural neoplasm › mediastinum neuroblastoma › mediastinum ganglioneuroblastoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.